HRP20131053T1 - Derivat oksadiazola koji djeluje na sfingozin-1-fosfat (s1p) - Google Patents
Derivat oksadiazola koji djeluje na sfingozin-1-fosfat (s1p) Download PDFInfo
- Publication number
- HRP20131053T1 HRP20131053T1 HRP20131053AT HRP20131053T HRP20131053T1 HR P20131053 T1 HRP20131053 T1 HR P20131053T1 HR P20131053A T HRP20131053A T HR P20131053AT HR P20131053 T HRP20131053 T HR P20131053T HR P20131053 T1 HRP20131053 T1 HR P20131053T1
- Authority
- HR
- Croatia
- Prior art keywords
- diseases
- conditions
- compound
- condition
- lupus erythematosus
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- KYDLFNMKNFOMEK-UHFFFAOYSA-N 3-[6-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]-5-methyl-3,4-dihydro-1h-isoquinolin-2-yl]propanoic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C(=C3CCN(CCC(O)=O)CC3=CC=2)C)=NO1 KYDLFNMKNFOMEK-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (6)
1. Spoj, naznačen time što je spoj 3-[6-(5-{3-cijano-4-[(1-metiletil)oksi]phenil}-1,2,4-oksadiazol-3-il)-5-metil-3,4-dihidro-2(1H)-izokinolinil]propanske kiseline,
i njegove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je stanje eritematozni lupus.
4. Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
5. Upotreba u skladu s patentnim zahtjevom 4, naznačena time što je stanje eritematozni lupus.
6. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0725101.0A GB0725101D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| PCT/EP2008/067963 WO2009080724A1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131053T1 true HRP20131053T1 (hr) | 2013-12-06 |
Family
ID=39048651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131053AT HRP20131053T1 (hr) | 2007-12-21 | 2013-11-06 | Derivat oksadiazola koji djeluje na sfingozin-1-fosfat (s1p) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8278324B2 (hr) |
| EP (2) | EP2225233B1 (hr) |
| JP (1) | JP2011506568A (hr) |
| KR (1) | KR20100108568A (hr) |
| CN (1) | CN101945864A (hr) |
| AU (1) | AU2008339987B2 (hr) |
| BR (1) | BRPI0821069A2 (hr) |
| CA (1) | CA2710067A1 (hr) |
| CO (1) | CO6290688A2 (hr) |
| CR (1) | CR11578A (hr) |
| DK (1) | DK2225233T3 (hr) |
| DO (1) | DOP2010000187A (hr) |
| EA (1) | EA018637B1 (hr) |
| ES (1) | ES2431795T3 (hr) |
| GB (1) | GB0725101D0 (hr) |
| HR (1) | HRP20131053T1 (hr) |
| IL (1) | IL206278A0 (hr) |
| MA (1) | MA31922B1 (hr) |
| NZ (1) | NZ585994A (hr) |
| PL (1) | PL2225233T3 (hr) |
| PT (1) | PT2225233E (hr) |
| UA (1) | UA102539C2 (hr) |
| WO (1) | WO2009080724A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2481740B1 (en) * | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| RU2654483C2 (ru) | 2013-02-20 | 2018-05-21 | ЭлДжи КЕМ, ЛТД. | Агонисты рецептора сфингозин-1-фосфата, способы их получения и фармацевтические композиции, содержащие эти соединения в качестве активного средства |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| EP1549640A4 (en) * | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| ES2379169T3 (es) * | 2003-05-19 | 2012-04-23 | Irm Llc | Composiciones y compuestos inmunosupresores |
| EP1628967B1 (en) * | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
| BRPI0410746A (pt) | 2003-05-19 | 2006-06-27 | Irm Llc | compostos e composições imunossupressoras |
| JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸 |
| US8039674B2 (en) * | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| AU2005299851B2 (en) * | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| BRPI0519012A2 (pt) * | 2004-12-13 | 2008-12-23 | Ono Pharmaceutical Co | derivado do Ácido aminocarboxÍlico e seu uso medicinal |
| AU2006226020A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as sphingosine-l-phosphate-1 receptor agonists |
| AU2006240789B2 (en) * | 2005-04-22 | 2010-03-04 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
| US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| MX2008002540A (es) | 2005-08-23 | 2008-03-14 | Irm Llc | Compuestos inmunosupresores y composiciones. |
| BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
| WO2008064337A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2007
- 2007-12-21 GB GBGB0725101.0A patent/GB0725101D0/en not_active Ceased
-
2008
- 2008-12-19 BR BRPI0821069-1A patent/BRPI0821069A2/pt not_active IP Right Cessation
- 2008-12-19 UA UAA201009200A patent/UA102539C2/ru unknown
- 2008-12-19 EP EP08863529.7A patent/EP2225233B1/en active Active
- 2008-12-19 EP EP13182453.4A patent/EP2746254A3/en not_active Withdrawn
- 2008-12-19 ES ES08863529T patent/ES2431795T3/es active Active
- 2008-12-19 WO PCT/EP2008/067963 patent/WO2009080724A1/en active Application Filing
- 2008-12-19 DK DK08863529.7T patent/DK2225233T3/da active
- 2008-12-19 JP JP2010538740A patent/JP2011506568A/ja not_active Ceased
- 2008-12-19 NZ NZ585994A patent/NZ585994A/en not_active IP Right Cessation
- 2008-12-19 EA EA201070781A patent/EA018637B1/ru not_active IP Right Cessation
- 2008-12-19 KR KR1020107016169A patent/KR20100108568A/ko not_active Application Discontinuation
- 2008-12-19 AU AU2008339987A patent/AU2008339987B2/en not_active Ceased
- 2008-12-19 US US12/747,191 patent/US8278324B2/en not_active Expired - Fee Related
- 2008-12-19 PT PT88635297T patent/PT2225233E/pt unknown
- 2008-12-19 CA CA2710067A patent/CA2710067A1/en not_active Abandoned
- 2008-12-19 CN CN2008801273526A patent/CN101945864A/zh active Pending
- 2008-12-19 PL PL08863529T patent/PL2225233T3/pl unknown
-
2010
- 2010-02-24 US US12/711,318 patent/US20100152235A1/en not_active Abandoned
- 2010-06-10 IL IL206278A patent/IL206278A0/en unknown
- 2010-06-16 MA MA32924A patent/MA31922B1/fr unknown
- 2010-06-18 DO DO2010000187A patent/DOP2010000187A/es unknown
- 2010-06-21 CO CO10074471A patent/CO6290688A2/es active IP Right Grant
- 2010-07-21 CR CR11578A patent/CR11578A/es not_active Application Discontinuation
-
2013
- 2013-11-06 HR HRP20131053AT patent/HRP20131053T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008339987B2 (en) | 2013-03-21 |
| CA2710067A1 (en) | 2009-07-02 |
| WO2009080724A1 (en) | 2009-07-02 |
| EP2225233B1 (en) | 2013-09-04 |
| CO6290688A2 (es) | 2011-06-20 |
| US8278324B2 (en) | 2012-10-02 |
| EP2225233A1 (en) | 2010-09-08 |
| DOP2010000187A (es) | 2010-08-15 |
| PT2225233E (pt) | 2013-11-22 |
| US20100273827A1 (en) | 2010-10-28 |
| EA018637B1 (ru) | 2013-09-30 |
| CN101945864A (zh) | 2011-01-12 |
| GB0725101D0 (en) | 2008-01-30 |
| CR11578A (es) | 2010-09-23 |
| ES2431795T3 (es) | 2013-11-28 |
| EA201070781A1 (ru) | 2010-12-30 |
| KR20100108568A (ko) | 2010-10-07 |
| IL206278A0 (en) | 2010-12-30 |
| MA31922B1 (fr) | 2010-12-01 |
| AU2008339987A1 (en) | 2009-07-02 |
| EP2746254A2 (en) | 2014-06-25 |
| US20100152235A1 (en) | 2010-06-17 |
| PL2225233T3 (pl) | 2014-01-31 |
| NZ585994A (en) | 2012-02-24 |
| EP2746254A3 (en) | 2014-10-15 |
| BRPI0821069A2 (pt) | 2015-06-16 |
| UA102539C2 (ru) | 2013-07-25 |
| DK2225233T3 (da) | 2013-10-14 |
| JP2011506568A (ja) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131053T1 (hr) | Derivat oksadiazola koji djeluje na sfingozin-1-fosfat (s1p) | |
| JP2010513397A5 (hr) | ||
| JP2016515536A5 (hr) | ||
| NZ597596A (en) | Bicyclic aryl sphingosine 1-phosphate analogs | |
| KR101624020B1 (ko) | 퀴놀리논 유도체 | |
| JP5575357B2 (ja) | 組織因子産生抑制剤 | |
| JP2014520809A5 (hr) | ||
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| JP6238460B2 (ja) | 脂質異常症治療剤 | |
| NZ585995A (en) | 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases | |
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| JP2009525340A5 (hr) | ||
| US10314836B2 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| DE60203623T2 (de) | Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren | |
| JP2017505293A5 (hr) | ||
| JP2019509315A5 (hr) | ||
| US20130338136A1 (en) | Novel indole modulators of s1p receptors | |
| JP2016512227A5 (hr) | ||
| JPWO2017086430A1 (ja) | Ｎａｓｈの治療又は予防のための医薬組成物 | |
| TW201632499A (zh) | Ｕｒａｔ１抑制劑 | |
| RU2017131522A (ru) | (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота | |
| US8729062B2 (en) | Benzyl azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | |
| TWI691331B (zh) | 脂質異常症治療劑 | |
| JP2009511450A5 (hr) | ||
| BR112014011518A2 (pt) | liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida |